Authors: MEHTA MU LESKO LJ CHING ML

Citation: Mu. Mehta et al., COMPARISON OF CLINICAL-PHARMACOLOGY (CP) AND BIOPHARMACEUTICS (BP) STUDIES SUBMITTED IN NDAS DURING 1995 AND 1997, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 42-42

Authors: MEHTA MU LESKO LJ

Citation: Mu. Mehta et Lj. Lesko, A SURVEY OF CLINICAL-PHARMACOLOGY (CP) AND BIOPHARMACEUTICS (BP) STUDIES SUBMITTED IN NDAS DURING THE PERIOD OF OCTOBER 1994 TO SEPTEMBER 1995, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 5-5

Authors: KELLOFF GJ JOHNSON JR CROWELL JA BOONE CW DEGEORGE JJ STEELE VE MEHTA MU TEMECK JW SCHMIDT WJ BURKE G GREENWALD P TEMPLE RJ

Citation: Gj. Kelloff et al., APPROACHES TO THE DEVELOPMENT AND MARKETING APPROVAL OF DRUGS THAT PREVENT CANCER, Cancer epidemiology, biomarkers & prevention, 4(1), 1995, pp. 1-10

Authors: KELLOFF GJ JOHNSON JR CROWELL JA BOONE CW DEGEORGE JJ STEELE VE MEHTA MU TEMECK JW SCHMIDT WJ BURKE G GREENWALD P TEMPLE RJ

Citation: Gj. Kelloff et al., GUIDANCE FOR DEVELOPMENT OF CHEMOPREVENTIVE AGENTS, Journal of cellular biochemistry, 1994, pp. 25-31